Sigma-Aldrich Welcomes Dublin City University to the RNAi Partnership Program
News Dec 05, 2006
Sigma-Aldrich a member of The RNAi Consortium proudly welcomes Dublin City University to the RNAi Partnership Program.
As one of the early members of the RNAi Partnership Program, Dublin City University gains access to cutting-edge products in Sigma-Aldrich's functional genomics portfolio, including MISSION™ TRC shRNA libraries that target more than 15,000 human and another 15,000 mouse genes
Through the RNAi Partnership Program, Sigma-Aldrich aims to establish collaborations with select academic institutions to advance functional genomics research by aiding academic researchers with early exposure to emerging new techniques, a broad portfolio of intellectual property and special partnership pricing on its extensive RNAi product lines.
Members of the RNAi Partnership Program enjoy unique access to cutting-edge tools for studying the underlying cause of disease and elucidating basic gene function.
"We are always looking for ways to work more closely with our customers, enabling them to be constantly involved in pushing forward the boundaries of research with the latest cutting-edge technologies," said John Lewis, Country Manager, Sigma-Aldrich Ireland.
"We are delighted to have Dr. Ronan Murphy and the Vascular Health Research Group in Dublin City University closely involved with the Sigma-Aldrich RNAi Partnership Program. We hope that this will be one of many occasions where we can support our colleagues in academia by this type of partnership."
Ronan Murphy, a Group Leader at the Vascular Health Research Centre, Dublin City University, said: "We are delighted to join the Sigma-Aldrich RNAi Partnership Program and look forward to a productive collaboration.
We currently study the regulation of integrin receptors in cells, focusing mainly on their role in vascular disease. The work has major relevance, through collaborations, in areas such as Immunology, Hematology, Cancer and Neuro biology.
Having identified a large number of genes potentially involved in vascular disease, access to the TRC MISSION shRNA Library will greatly accelerate our ability to prioritize genes that are functionally relevant."
Murphy and his research group, including Paul Fitzpatrick and Mishan Britto, along with colleague Dr. Philip Cummins, have already begun utilizing this powerful technology in their studies.
Sigma-Aldrich's product offering includes various products positioned along the functional genomic research workflow, such as the lentivirus-based MISSION TRC shRNA libraries, activated lentiviral particles, custom siRNA and QPCR reagents.
Existing members of the Sigma RNAi Partnership Program include Rutgers University, University of Medicine & Dentistry New Jersey, The Wistar Institute, Washington University of Saint Louis, Tufts University, Moore's Cancer Center UCSD, University of Edinburgh, among others.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019